Pediatrix Medical Group Azioni (NYSE: MD)

Ultime notizie per Pediatrix Medical Group (NYSE:MD) Azioni

Pediatrix Medical Group

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group Inc

Moeda Loyalty Points

Spectral AI Inc

MAEDA KOSEN CO LTD by MAEDA KOSEN CO LTD.

MDA Space Ltd

DAVI LUXURY BRAND GRP INC by Davi Luxury Brand Group, Inc.

Davi Luxury Brand Group Inc

Media Way Corp

MongoDB Inc

MEDLAB CLINICAL LTD by Medlab Clinical Ltd.

Medlab Clinical Ltd

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings LLC

TrivarX Ltd

MEDIBANK PRIVATE UNSP/ADR by MEDIBANK PRIVATE LTD

Medibank Pvt Ltd

MEDIBANK PRIVATE LTD by MEDIBANK PRIVATE LTD

UBS LUX SOL BANK BND USD ACC ETF

UBS LUX SOL BANK BND USDDIS ETF

M.D.C. Holdings, Inc. Com.

MEDICAL CARE TECHS INC by Medical Care Technologies Inc.

Medical Care Technologies Inc

Chapters Group AG

Medincell SA

MEDICAN ENTERPRISES INC by Medican Enterprises Inc

Medican Enterprises Inc

VictoryShares THB Mid Cap ETF

Media Do Co Ltd

MDM GROUP INC by MDM Group, Inc.

MERIDIAN ENERGY LTD by Meridian Energy LTD

Meridian Energy Ltd

MANDATUM OYJ U/ADR by MANDATUM OYJ

MEDICAL DEV INTL LTD ORD by Medical Developments International Ltd.

Medical Developments International Ltd

Media 100 Inc

ARNOLDO MONDADORI E U/ADR by Arnoldo Mondadori Editore Spa

Arnoldo Mondadori Editore SpA

First Trust Indxx Medical Devices ETF

MELCO INTL DEVEL by Melco International Development Limited

Melco International Development Ltd

MELCO INTL DEV LTD UNSADR by Melco International Development Limited

MADISON TECHNOLOGIES INC by Madison Technologies Inc.

Madison Technologies Inc

MediaG3 Inc

Medigene AG Namen-Akt. nach Kapitalherabsetzung

Medigene AG

MELODIOL GLBL HLTH 2028 by MELODIOL GLOBAL HEALTH LTD

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Medgroup Inc

Mediaco Holding Inc. - Class A Common Stock

MediaCo Holding Inc

Mediobanca SpA

MEDIOBANCA SPA UNSP/ADR by MedioBanca SpA

MIDLAND IC&I LTD by Midland IC&I Ltd

Modec Inc

MedGen Inc

MEDITE CANCER DIAGNOSTICS by Medite Cancer Diagnostics, Inc.

Medite Cancer Diagnostics Inc

Multi-Asset Diversified Income Index Fund

MR D I Y GROUP M BERHAD by MR D I Y GROUP M BERHAD

Mr D.I.Y. Group (M) Bhd

MDJM Ltd

Mdechem Inc

MEDICAL INTL TECH INC by Medical International Technology, Inc.

Medical International Technology Inc

MEDLEY MANAGEMENT A by Medley Management, Inc.

Medley Management Inc

MDNA Life Sciences Inc

EA Series Trust Morgan Dempsey Large Cap Value ETF

MEDLIVE TECH CO LTD U/ADR by MEDLIVE TECHNOLOGY CO LTD

MEDLEY Inc

Mondelez International, Inc. - Class A Common Stock

Mondelez International Inc

MONDELEZ INTERNATIONAL CL A ORD

MIDAS MINERALS LTD by MIDAS MINERALS LTD.

MEDINAH MINERALS INC by Medinah Minerals, Inc.

Medinah Minerals Inc

MDM Permian Inc

Medmix AG

MEDICENNA THERAPEUTICS CORP COM

MEDICENNA THERA CORP by Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp

Medinotec Inc

MCDONALDS HLDGS JAPAN ORD by McDonalds Hldgs Co Japan Ltd.

McDonald's Holdings Co (Japan) Ltd

MIDNIGHT SUN MINING CORP by Midnight Sun Mining Corp

Midnight Sun Mining Corp

MAIDEN LANE JEWELRY LTD by Maiden Lane Jewelry, Ltd.

Maiden Lane Jewelry Ltd

Mednow Inc

MANDARIN ORIENTAL INTERNATIONAL ORD

Mandom Corp

MAISONS DU MONDE SA by Maisons Du Monde SA

Maisons du Monde France SA

MADISON PAC PPTYS B ORD by Madison Pacific Properties Inc.

Madison Pacific Properties Inc

MedPeer Inc

Northern Lights Fund Trust IV Monarch Dividend Plus Index ETF

MEDICUS PHARMA LTD by MEDICUS PHARMA LTD.

Medicus Pharma Ltd

PT MD Entertainment Tbk

Medra Corp

Midori Group Inc

Mandarake Inc

MODERN MOBILITY AIDS INC by Modern Mobility Aids, Inc.

Modern Mobility Aids Inc

Modern Mining Technology Corp

Modern Plant Based Foods Inc

MODERN PLT BASE FOODS INC by Modern Plant Based Foods Inc.

Medalist Diversified REIT, Inc. - Common Stock

Medalist Diversified REIT Inc

Medalist Diversified REIT, Inc. - Series A Cumulative Redeemable Preferred Stock

MEDARTIS HOLDING AG by MEDARTIS HOLDING AG

Medartis Holding AG

Veradigm Inc

MATRIX DENTURE SYS INTL by Matrix Denture Systems International, Inc.

Matrix Denture Systems International Inc

TEN SIXTY FOUR LTD by TEN SIXTY FOUR LTD.

Ten Sixty Four Ltd

MINSUD RESOURCES ORD by Minsud Resources Corp

Minsud Resources Corp

Ultimus Managers Trust Westwood Salient Enhanced Midstream Income ETF

Medtronic PLC

Measurable Data Token - United States Dollar

<p>Truist Securities  analyst David Macdonald   maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and raises the price target from $10 to $13.</p>


News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Pediatrix Medical Group, Raises Price Target to $13

<p>Analysts' ratings for Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.62, a high estimate of $14.00, and a low estimate of $8.00. This upward trend is apparent, with the current average reflecting a 21.37% increase from the previous average price target of $8.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727373658_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Pediatrix Medical Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Slevin</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pediatrix Medical Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Pediatrix Medical Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Pediatrix Medical Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pediatrix Medical Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Pediatrix Medical Group Better</h2>
<p>Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.</p>
<h3>Pediatrix Medical Group: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pediatrix Medical Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>0.74%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Pediatrix Medical Group's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-30.34%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-19.59%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Pediatrix Medical Group's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.35%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.99</strong>, Pediatrix Medical Group faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


4 Analysts Have This To Say About Pediatrix Medical Group

WIIM

Pediatrix Medical Group shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $8 to $14

<p>Jefferies  analyst Jack Slevin   upgrades Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) from Hold to Buy and raises the price target from $8 to $14.</p>


Upgrades

Jefferies Upgrades Pediatrix Medical Group to Buy, Raises Price Target to $14

<p>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.12, a high estimate of $10.50, and a low estimate of $8.00. Surpassing the previous average price target of $8.75, the current average has increased by 4.23%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723737648_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Pediatrix Medical Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Hold</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pediatrix Medical Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Pediatrix Medical Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Pediatrix Medical Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pediatrix Medical Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Pediatrix Medical Group: A Closer Look</h2>
<p>Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.</p>
<h3>Understanding the Numbers: Pediatrix Medical Group's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Pediatrix Medical Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.74%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Pediatrix Medical Group's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-30.34%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Pediatrix Medical Group's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-19.59%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Pediatrix Medical Group's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.35%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Pediatrix Medical Group's debt-to-equity ratio is below the industry average. With a ratio of <b>0.99</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From Pediatrix Medical Group Analyst Ratings

<p>Truist Securities  analyst David Macdonald   maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and raises the price target from $8 to $10.</p>


Truist Securities Maintains Hold on Pediatrix Medical Group, Raises Price Target to $10

<p>UBS  analyst A.J. Rice   maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Neutral and raises the price target from $9 to $10.5.</p>


UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $10.5

Pediatrix Medical Group shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

Guidance

Pediatrix Medical Anticipates Adjusted EBITDA Of $200M - $220M

<p>The transition will be effective on or about October 1, 2024, following the anticipated completion of the next phase of the Company&#39;s previously announced transition of its outsourced enterprise revenue cycle management services and the advancement of the Company&#39;s planned portfolio management activities.</p>
<p>The Company also announced today that its board of directors has appointed Ms. Mary Ann E. Moore to serve as the Company&#39;s Chief Administrative Officer, in addition to her existing roles as the Company&#39;s Executive Vice President, General Counsel and Secretary, effective as of August 1, 2024.</p>
<p>In addition, Pediatrix announced that Curtis B. Pickert, M.D. has transitioned from his role as the Company&#39;s Executive Vice President, Chief Operating Officer and will now serve as Pediatrix&#39;s Executive Vice President, Chief Physician Executive, effective as of August 1, 2024.</p>


Management

Pediatrix Medical Appoints Kasandra Rossi To Succeed Marc Richards As Executive Vice President, CFO And Treasurer

<p>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. This is a 12.82 percent decrease over earnings of $0.39 per share from the same period last year.  The company reported quarterly sales of $504.296 million which missed the analyst consensus estimate of $505.495 million by 0.24 percent.  This is a 0.74 percent increase over sales of $500.577 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Pediatrix Medical Group Q2 2024 Adj. EPS $0.34 Beats $0.31 Estimate, Sales $504.296M Miss $505.495M Estimate

<p>Truist Securities  analyst David Macdonald   maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and lowers the price target from $10 to $8.</p>


Truist Securities Maintains Hold on Pediatrix Medical Group, Lowers Price Target to $8

<p>Deutsche Bank  analyst Pito Chickering   upgrades Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) from Sell to Hold and maintains the price target from $8 to $8.</p>


Deutsche Bank Upgrades Pediatrix Medical Group to Hold, Maintains Price Target to $8

<p>In the preceding three months, 4 analysts have released ratings for Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.5, a high estimate of $10.00, and a low estimate of $9.00. This current average has decreased by 6.13% from the previous average price target of $10.12. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715799632_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Pediatrix Medical Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$10.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pediatrix Medical Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Pediatrix Medical Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pediatrix Medical Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pediatrix Medical Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Pediatrix Medical Group Better</h2>
<p>Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.</p>
<h3>Financial Milestones: Pediatrix Medical Group's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Pediatrix Medical Group showcased positive performance, achieving a revenue growth rate of <strong>0.83%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Pediatrix Medical Group's net margin excels beyond industry benchmarks, reaching <strong>0.81%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Pediatrix Medical Group's ROE excels beyond industry benchmarks, reaching <strong>0.47%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Pediatrix Medical Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.18%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Pediatrix Medical Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.91</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 4 Analyst Ratings For Pediatrix Medical Group

<p>Truist Securities  analyst David Macdonald   maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and maintains $10 price target.</p>


Truist Securities Maintains Hold on Pediatrix Medical Group, Maintains $10 Price Target

<p>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is a 13.04 percent decrease over earnings of $0.23 per share from the same period last year.  The company reported quarterly sales of $495.10 million which missed the analyst consensus estimate of $499.08 million by 0.80 percent.  This is a 0.83 percent increase over sales of $491.01 million the same period last year.</p>


Pediatrix Medical Group Q1 Adj $0.20 Beats $0.19 Estimate, Sales $495.10M Miss $499.08M Estimate

<p>Jefferies  analyst Brian Tanquilut   maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and lowers the price target from $10 to $9.</p>


Comments

Pediatrix Medical Group

Notizie

Ultime notizie per Pediatrix Medical Group (NYSE:MD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO